VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA Biotech AG (VRXA) reported initial in vivo proof-of-concept for its BiTAC-ADC platform, demonstrating significant tumor regression in a breast cancer model with a single dose. The company noted no observed body weight decrease in the study.

VERAXA Biotech AG (NASDAQ: VRXA) presented in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress. The data showed significant tumor regression in a breast cancer model with a single dose, while maintaining safety. The company highlights the potential for safer cancer treatments with comparable efficacy to conventional ADCs.

China SXT Pharmaceuticals (SXTC) shares surged 536% post-share consolidation, with recent financing plans. VERAXA Biotech (VRXA) rose 15% after adopting FDA-aligned methodologies. ArriVent BioPharma (AVBP) gained 12% despite a missed Phase 3 trial endpoint. SciSparc (SPRC) climbed 8% on quantum analysis advancements.

Veraxa Biotech AG (VRXA) shares rose 4.6% after appointing Raju Willener as CFO, effective immediately. Willener has over 30 years of experience in finance and previously served as CFO at Exentis Group AG. The company is advancing its BiTAC technology platform for cancer therapies. Willener replaces Carl von Halem.

VERAXA Biotech AG (NASDAQ: VRXA) appointed Carl von Halem as interim CFO, effective immediately, succeeding Torsten Bürgermeister. The company said it is in the final stages of discussions with a successor and will update the market later. The release cites von Halem’s prior CFO role at Xlife Science and other life-sciences experience.

Arm reported a favorable jury verdict in its litigation with Qualcomm, with the jury finding for Arm on four claims and awarding only $1 in damages on Qualcomm's other two claims. Arm stated it operated in good faith under its technology license agreement and remains focused on delivering technology and creating value for shareholders.